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The association between sodium-glucose cotransporter 2 inhibitors (SGLT2i’s) and lower
extremity amputation is unclear.
Purpose
To systematically review randomized control trials (RCTs) and observational studies quanti-
fying risk of lower extremity amputations associated with SGLT2i use.
Data sources and study selection
We searched PubMed, EMBASE, Scopus, and the Cochrane Central Register of Controlled
Trials from January 2011 to February 2020 for RCTs and observational studies including
lower extremity amputation outcomes for individuals with type 2 diabetes mellitus treated
with SGLT2i’s vs. alternative treatments or placebo.
Data extraction and synthesis
Two reviewers independently extracted data.
Main outcomes and measures
Our primary outcome was risk of lower limb amputation. Secondary outcomes included
peripheral arterial disease, peripheral vascular disease, venous ulcerations, and diabetic
foot infections. We also evaluated the risk of bias. We conducted random and fixed effects
relative risk meta-analysis of RCTs.
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Results
After screening 2,006 studies, 12 RCTs and 18 observational studies were included, of
which 7 RCTs and 18 observational studies had at least one event. The random effects
meta-analysis of 7 RCTs suggested the absence of a statistically significant association
between SGLT2i exposure with evidence of substantial statistical heterogeneity (n = 424/
23,716 vs n = 267/18,737 in controls; RR 1.28, CI’s 0.93–1.76; I2 = 62.0%; p = 0.12)
whereas fixed effects analysis showed an increased risk with statistical heterogeneity (RR
1.27, 1.09–1.48; I2 = 62%; p = 0.003). Subgroup analysis of canagliflozin vs placebo showed
a statistically significantly increased risk in a fixed effects meta-analysis (n = 2 RCTs, RR
1.59, 1.26–2.01; I2 = 88%; p = 0.0001) whereas the meta-analysis of dapagliflozin or empa-
gliflozin (n = 2 RCTs each) and a single RCT for ertugliflozin did not show a significantly
increased risk. The findings from observational studies were too heterogeneous to be
pooled in a meta-analysis and draw meaningful conclusions. Both randomized and observa-
tional studies were of generally good methodological quality.
Conclusions
Overall, there was no consistent evidence of SGLT2i exposure and increased risk of ampu-
tation. The increased risk of amputation seen in the large, long-term Canagliflozin Cardio-
vascular Assessment Study (CANVAS) trial for canagliflozin, and select observational
studies, merits continued exploration.
Introduction
In 2017, 30.3 million individuals in the United States were estimated to have diabetes, increas-
ing their risk for microvascular and macrovascular morbidities [1]. Lifestyle modification and
pharmacotherapy can help to prevent these complications by reducing glycemic burden and
promoting glycemic control.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i’s) are anti-hyperglycemic agents
(AHA) first approved by the U.S. Food Drug Administration (FDA) in 2013 for type 2 diabe-
tes. Unlike other diabetes treatments, SGLT2i’s, including canagliflozin, dapagliflozin, and
empagliflozin, inhibit renal glucose reabsorption, increasing glucose excretion and decreasing
plasma glucose concentrations. SGLT2i’s work independently of insulin production and offer
additional clinical benefits including weight loss [2] and reduced risk of major cardiovascular
events, heart failure and, all-cause death [3].
Against these potential benefits, in 2017, the FDA issued a Drug Safety Communication,
concluding that canagliflozin causes an increased risk of leg and foot amputation [4]. The FDA
based their decision on two clinical trials that found a statistically significantly greater risk of
amputation with canagliflozin compared to placebo (6.3 vs 3.4 participants with amputations
per 1000 patient-years, hazard ratio (HR) 1.97 95% confidence intervals (CI) 1.41–2.75) [5].
Those trials only studied canagliflozin and were not statistically powered to assess amputa-
tions, but evidence from a meta-analysis of randomized trials supported this assertion, finding
a statistically significant increase in risk of amputation for SGLT2i’s compared to active con-
trols or placebo (relative risk (RR) 1.44; CI 1.13–1.83) [3].
Despite this evidence, some observational studies have not detected an association [6][7] or
have found a lower risk of amputation from SGLT2i’s versus sulfonylureas [8], and the
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mechanism by which SGLT2i might increase the risk of amputations is unknown [9]. A review
of SGLT2i’s limited to randomized controlled trials published between January 2015 and June
2017 noted an increased risk of amputations in one trial [10]. In addition to updating this
prior review limited to RCTs on the outcome of amputations, we also included observational
studies and evaluated peripheral vascular events.
Methods
Systematic review registration
We conducted a systematic review and meta-analysis following a prespecified protocol pub-
lished in the PROSPERO International Prospective Register of Systematic Reviews [11]. We
followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
checklist (S1 Appendix).
Data sources and searches
We searched PubMed, EMBASE, Scopus, and the Cochrane Central Register of Controlled
Trials (CENTRAL), using combined text and Medical Subject Heading (MeSH) terms on
March 13, 2019, and updated our search on February 13, 2020 (S2 Appendix). The detailed
search strategy including MeSH terms used is published on PROSPERO (ID
CRD42019119069) [11]. We included studies published from 2011-present, as the first global
approval of a SGLT-2i occurred in 2011. No language restrictions were applied.
Study selection
We included randomized controlled trials (RCT) and observational studies, including retro-
spective or prospective cohort studies, case-control, and self-controlled studies. The included
studies enrolled subjects 18 years or older with type 2 diabetes receiving SGLT2i’s compared
against other AHAs or placebo. Two authors (JH and LO) independently reviewed titles and
abstracts of retrieved studies to identify those that potentially met inclusion criteria. Two team
members then retrieved and independently assessed the full text of potentially eligible studies.
Disagreements about the eligibility of studies were adjudicated by discussion between the two
review team members.
Outcomes extracted
Our primary outcome was risk of lower limb amputation. Secondary outcomes included
peripheral arterial disease, peripheral vascular disease, venous ulcerations, and diabetic foot
infections. We included studies that reported any of these outcomes as either a primary or sec-
ondary outcome with effect estimates such as odds ratios or risk ratios.
Data collection and analysis
We used duplicate extraction, with two study authors (JH and LO) independently extracting
relevant study characteristics and outcomes into a standardized form (S3 Appendix). In all
cases, we extracted study setting, study design, recruitment method, sample size, participant
demographics, patient inclusion and exclusion criteria, outcomes and times of measurement,
and information for assessment of risk of bias. For observational studies, we also extracted
total and median person-time observed by treatment group; outcome event rates; adjusted and
unadjusted hazard ratios; and demographic characteristics accounted for in propensity-score
matching of treatment and comparator groups. For RCTs, we extracted event counts or event
rates to generate odds ratios or relative risks.
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Risk of bias assessment
Two independent reviewers (JH and OM) assessed risk of bias based on the methodological
quality of the included studies. Risk of bias for the RCTs was assessed using the Cochrane Risk
of Bias Tool for Randomized Controlled Trials, which evaluated trials based on the presence
or absence of randomization sequence generation, allocation concealment, selective reporting,
blinding of participants and personnel, blinding of outcome assessment, incomplete outcome
data, and other forms of bias [12]. For observational studies, we used the Newcastle-Ottawa
Scale to rate studies on methods of addressing time-varying confounding, baseline confound-
ing, patient selection, classification of outcomes, deviations from the intended intervention,
missing data, measurement of outcomes, and selection of reported outcomes [13]. Disagree-
ments about the risk of bias assessment were adjudicated through discussion among the study
team. We reached final consensus prior to inclusion.
Data synthesis and analysis
Quantitative synthesis of RCTs. We pooled the results using a random-effects meta-anal-
ysis of RCTs, with risk ratios for binary outcomes, and calculated 95% confidence intervals
and p-values for each outcome. We also report results using fixed effects which are appropriate
when the number of studies is low. We assessed the amount of heterogeneity across the RCTs
examined using the I2, a measure of the amount of variation in outcomes due to variance in
true effect sizes rather than sampling error. Publication bias was assessed using Funnel plots.
All analyses were conducted in RevMan 5.3 [14].
We also conducted some subgroup analysis of RCTs. We conducted meta-analysis evaluat-
ing the risk of amputations for each individual SGLT2 inhibitor and the meta-analysis of
SGLT2 inhibitors vs placebo in the RCTs.
Qualitative synthesis of observational studies. We synthesized our findings in narrative
form organized by study design, comparison group, and safety outcome. We summarized the
results of individual studies, describing event rates as well as risk ratios, odds ratios or adjusted
hazard ratios (observational studies) for developing the vascular outcomes of interest. In our




The PRISMA flow sheet for studies is shown in Fig 1. A total of 2,622 citations were available
for screening, and 698 articles were duplicates. One-hundred and seventeen articles remained
after title and abstract review, and 30 after full-text screening. We evaluated a total of 12 RCTs
(Table 1) and 18 observational studies (Table 2).
Results of RCTs. Study design and characteristics. We included 12 RCTs in our qualitative
synthesis. The 12 RCTs included 45,551 participants: 25,593 were randomized to receive an
SGLT2 inhibitor, 600 received an alternative treatment, and 19,358 received a placebo
(Table 1). The trials enrolled from 210 participants to 17,160 participants and ranged in dura-
tion from 12 weeks to 8 years. The study design and characteristics of included RCTs are
shown in Table 1. Four studies examined empagliflozin [15][16][17][18], three studies exam-
ined dapagliflozin [19][20][21], two studies examined canagliflozin [22][23], and 1 each exam-
ined topogliflozin [24], ertugliflozin [25], and ipragliflozin [26]. Eleven studies used a placebo
control and the ertugliflozin study used glimepiride as the control. Five studies, two examining
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empagliflozin and 1 each examining dapagliflozin, ipragliflozin, and topogliflozin, reported 0
amputation events in both arms and thus seven studies were available for meta-analysis.
Risk of bias of RCTs
Overall, there was little to no evidence of major bias in the included RCTs (S1 Fig). However,
reporting of study methodology was often incomplete. For example, the method of randomiz-
ing participants was only reported in 7 of 12 RCTs. In cases in which randomization method
was not specified, we assumed truly random allocation based on its fundamental and univer-
sally recognized importance (“probable yes”). Concealment of the allocation sequence was
never reported. Baseline demographic characteristics were uniformly well presented and loss
to follow-up was relatively low.
Meta-analysis of the risk of amputation with SGLT2 inhibitors vs controls
in RCTs
Fig 2 depicts the meta-analysis examining the association between SGLT2i exposure and lower
extremity amputation based on 7 RCTs. The random effects meta-analysis of 7 RCTs suggested
the absence of a statistically significant association between SGLT2i exposure with evidence of
substantial statistical heterogeneity (n = 424/23,716 vs n = 267/18,737 in controls; RR 1.28,
CI’s 0.93–1.76; I2 = 62.0%; p = 0.12) whereas fixed effects analysis showed an increased risk
with statistical heterogeneity (RR 1.27, 1.09–1.48; I2 = 62%; p = 0.003).
Fig 1. Prisma flow diagram.
https://doi.org/10.1371/journal.pone.0234065.g001
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Subgroup analysis
Subgroup analysis of canagliflozin vs placebo showed a statistically significantly increased risk
in a fixed effects meta-analysis (n = 2 RCTs, RR 1.59, 1.26–2.01; I2 = 88%; p = 0.0001) whereas
the meta-analysis of dapagliflozin or empagliflozin (n = 2 RCTs each) did not show a signifi-
cantly increased risk (Table 3). Although we present both the results for the fixed and random
effect meta-analysis of dapagliflozin, empagliflozin and canagliflozin vs placebo, the fixed
effects results are considered most appropriate when number of studies is low (n = 2 for each
subgroup).
Only one study evaluated the risk of SGLT2i vs active comparator and reported no risk
[27]. The meta-analysis of remaining 6 placebo-controlled studies showed no significant
increased risk of amputations associated with SGLT2 inhibitors in a random effects meta-anal-
ysis (RR 1.27,0.91–1.77; I2 = 68%).
Results of observational studies. Study characteristics. Of the 18 observational studies
included, 15 were retrospective cohort studies, 2 were prospective cohort studies, and 1 was a
case-control study. The studies used claims records of more than 6.4 million individuals;
860,120 (13.3%) of them were classified as new users of SGLT2i’s. The study design and char-
acteristics of included observational studies are shown in Table 2.
Risk of bias of observational studies
The included observational studies were of generally good quality (S2 Fig), although 3 lacked a
control arm and 2 did not adjust for potential baseline confounding between exposed and
non-exposed individuals. The included studies were broadly similar in terms of ascertainment
of exposure and assessment of outcomes (i.e. electronic health claims and administrative
codes), but varied when it came to representativeness of the exposed cohort. In addition, only
8 studies explicitly assessed and excluded amputation at baseline. Most studies adjusted for
confounding; 12 used propensity score matching on a broad array of baseline characteristics,
and one matched patients based on a predefined list of baseline factors. In all studies, the
length of follow-up observation was relatively sufficient to assess the outcomes of interest.
Qualitative synthesis of observational studies
Eleven examined SGLT2i’s as a class [28][9][8][29][30][31][32][33][34][35][36], 4 examined
canagliflozin alone [6][37][38][39], 2 examined empagliflozin alone [46][47], and 1 examined
dapagliflozin alone [42]. Comparator products varied significantly among studies, with 6 each
using DPP-4 inhibitors (DPP-4i) and GLP-1 agonists (GLP-1a); 3 using all non-SGLT2i’s
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Table 2. Characteristics of included observational studies (N = 18).
Source Treatment
Group
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https://doi.org/10.1371/journal.pone.0234065.t002
Fig 2. A. Fixed-effects meta-analysis- SGLT2i’s vs. placebo/glimepiride. B. Random-effects meta-analysis- SGLT2i’s
vs. placebo/glimepiride.
https://doi.org/10.1371/journal.pone.0234065.g002
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comparison group and 1 with no testing of inter-group differences. Several studies included
multiple comparator classes.
Across all 19 reported active-comparator analyses in the 15 studies with a comparator, 6
reported a decreased risk of amputation among SGLT2i users, though level of adjustment, sta-
tistical significance, and comparator varied. The adjusted effect estimates of 13 analyses
showed an increased risk of amputation; again, significance and comparator varied. Inter-
study heterogeneity prevented any meta-analysis of analyses comparing any SGLT2i therapy
to a specific comparator.
Secondary outcomes
Randomized controlled trials. None of the included RCTs measured any of the second-
ary outcomes of interest.
Observational studies. One included study reported on peripheral vascular disease and
venous ulcerations, reporting three separate analyses for each [9]. The adjusted HR for inci-
dent peripheral vascular disease comparing SGLT2’i vs. DPP-4i’s, GLP-1a’s, and all non-
SGLT2i AHAs, respectively, were 0.88 (95% CI 0.79–0.96), 0.95 (95% CI 0.84–1.07), and 1.11
95% CI (1.02–1.22), and for venous ulceration 1.12 (95% CI 0.91–1.39), 0.97 (95% CI 0.75–
1.26), and 1.34 (95% CI 1.10–1.61). No studies examined peripheral arterial disease or diabetic
foot infections.
Discussion
More than seven years after their market debut in the United States, questions remain regard-
ing the potential association between SLGT2i’s and lower extremity amputation. In this sys-
tematic review and meta-analysis, amputation risk varied widely among the studies that were
synthesized; data from randomized studies comparing five different SGLT2i’s to placebo or gli-
mepiride indicated a statistically significant elevated amputation risk in one large, long-term
trial for canagliflozin only, and a non-significant association overall. Subgroup analysis showed
a statistically significantly increased risk for canagliflozin alone.
Among observational data, study heterogeneity and potential confounding prevented the
conduct of meta-analysis, but we found that two thirds of analyses comparing SGLT-2i prod-
ucts against GLP-1a’s, DPP-4i’s, sulfonylureas and other AHA’s reported an elevated risk of
amputation among SGLT-2i’s, though the effect was rarely statistically significant. Taken
Table 3. Subgroup analysis of risk of amputation among individual SGLT2i’s.
No. of
studies
No. of events in SGLT-2i
arm/ Total no. of
participants
No. of events in control/





Fixed effects; I2, %
Empagliflozin vs placebo (Yabe et al [21], Zinman et al
[16])




Dapagliflozin vs control (Wiviott et al [20], Pollock et al
[21])




Canagliflozin vs placebo (Perkovic et al [23], Matthews
et al [24])




SGLT2 inhibitors vs placebo
SGLT2 inhibitors vs placebo (Yabe et al [18], Zinman
et al [16], Wiviott et al [20], Pollock et al [21], Perkovic
et al [22], Matthews et al [23])




SGLT2i’s sodium-glucose cotransporter 2 inhibitors; No. number; IV inverse variance; RR relative risk
https://doi.org/10.1371/journal.pone.0234065.t003
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together, the preponderance of evidence suggested no consistent evidence of association
between SGLT2i exposure and increased risk of amputation among adults with type 2 diabetes,
though the risk associated with canagliflozin exposure bears further scrutiny. These findings
are important given how commonly SGLT2i’s are prescribed, as well as ongoing questions
regarding their optimal role in the treatment of a common and costly chronic disease.
Our review underscores the heterogeneous literature regarding SGLT2i’s and adverse
events such as lower extremity amputation. The studies were diverse with respect to study
design, duration, reference product, comparator, and statistical and reporting methods.
Although we were unable to combine all studies for meta-analysis due to heterogeneity, we
conducted several meta-analyses that included comparisons of the SGLT2i’s class or individual
members of that class against placebo, but not GLP-1a’s, DPP-4i’s, sulfonylureas or aggregated
non-SGLT2i therapies, to minimize the possibility of confounding by indication and disease
severity. In our meta-analyses there were differences between the models due to the effect of
smaller studies, which have relatively greater weight in random than fixed effects models.
Marked heterogeneity in the included studies argued for use of random effects as primary
results [43], except when the number of studies is low, although these may not always provide
a conservative estimate of risk [44].
Our findings bear similarities and differences to other meta-analysis on this topic. In addi-
tional to the previously referenced meta-analysis [10], two recent meta-analyses of RCTs pub-
lished in May and September 2019, respectively, found a non-significant increased risk of
amputation among three large studies assessing canagliflozin, dapagliflozin, and empagliflozin
[45][46]. The overall finding of non-significance in these studies mirrors our own, while in
contrast, we were able to meta-analyze the results for three individual products, and our find-
ings were also supplemented by the inclusion of observational studies that similarly were
inconclusive in aggregate but also were suggestive an elevated risk for canagliflozin.
One important consideration is whether the heterogeneous effect seen in our study may be
limited to a particular drug and not a class effect [47]. We found that among discrete SGLT-2i
products meta-analyzed using RCT data, only canagliflozin carried a statistically significant
elevated risk of amputation compared with placebo treatment. This is important, and bears
further scrutiny in future investigations. Similarly, if the risk is limited to those with high base-
line CVD such as those enrolled in the Canagliflozin Cardiovascular Assessment Study (CAN-
VAS) program, an individual participant data meta-analysis may provide further information.
Studies that evaluate the biological mechanisms that could account for any such risk of
SGLT2i’s are also needed. For example, it is unclear whether any increased risk of amputation,
should it be present, is due to the diuretic effect of SGLT2i’s; some studies have suggested that
diuretics may increase the risk of amputations in patients with type 2 diabetes [48][49].
The potential risks of SGLT2i’s must be balanced with their potential benefits, including
improved glycemic control and reduced rate of major adverse cardiovascular events (MACE)
as demonstrated for empagliflozin in the BI 10773 [Empagliflozin] Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial [16], for cana-
gliflozin in the CANVAS program, which included both the CANVAS and CANVAS-RENAL
trials, and for dapagliflozin in the Dapagliflozin Effect on Cardiovascular Events–Thromboly-
sis in Myocardial Infarction (DECLARE-TIMI) trial [20]. Data from these trials suggest signifi-
cant cardiovascular benefits for individuals with pre-existing CVD. This evidence has led FDA
to expand the label for empagliflozin and canagliflozin for use to lower cardiovascular risk in
patients with type 2 diabetes and cardiovascular disease [50], and it has shaped practice guide-
lines that underscore the selection of agents, especially for those with cardiovascular disease,
based on their proven ability to reduce major adverse cardiovascular events and/or cardiovas-
cular mortality [51][52]. As with other pharmacologic treatments for diabetes, these features of
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SGLT2i’s underscore the importance of individualized selection of therapies based on factors
including regimen effectiveness, adverse event profile, formulation, therapeutic complexity,
cost, and patient preference.
Despite its rigor, our study has limitations, some reflecting features of the individual studies
that we examined. Although RCTs are the principal means of establishing the efficacy of
drugs, they may have limited statistical power to detect infrequent adverse events, such as
amputations in real-world patients, which occurs at a rate of 5.0 per 1,000 in individuals with
type 2 diabetes [53]. Thus these RCTs are quite susceptible to type 2 error [54]. None of the
included trials pre-specified lower extremity amputations as an outcome of ascertainment,
rather these data were collected as adverse events, which may result in misclassification of out-
comes; any such misclassification is likely to be non-differential and would bias the results
towards the null. In addition, we pooled analyses with limited clinical information on patients’
baseline cardiovascular risks, and no individual-level patient data was available to carry out
prespecified subgroup analysis based on preexisting CVD status. Also, the studies reflected
considerable heterogeneity, preventing more precise estimates of the associations of interest.
Our study focused on the peer-reviewed literature, and it is possible that trial registries, grey
literature, or other non-peer reviewed, publicly available information might contain additional
data relevant to the association between SGLT2i’s, lower extremity amputation, and other car-
diovascular events.
Conclusion
Given the elevated incidence of cardiovascular disease among individuals with type 2 diabetes,
the cardiovascular risks, and benefits, of pharmacologic treatments for diabetes are of peren-
nial interest and concern. Despite reproducible, well-controlled evidence of significant reduc-
tions in major adverse cardiovascular events associated with SGLT2i’s compared with placebo,
the association between SGLT2i’s and lower extremity amputation has been much less clear.
In this systematic review and meta-analysis, we found no consistent evidence of SGLT2i expo-
sure and increased risk of amputation. The increased risk of amputation observed in the large,
long-term CANVAS trial with canagliflozin, and select observational studies, merits further
exploration.
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